Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Express Scripts
AstraZeneca
Fuji
McKinsey
Moodys
Healthtrust
UBS
Colorcon

Generated: December 11, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CONCERTA

« Back to Dashboard

Clinical Trials for Concerta

Trial ID Title Status Sponsor Phase Summary
NCT00069927 Adderall XR Compared With Concerta in Treating Young Cancer Patients With Memory, Attention, and Depression Terminated National Cancer Institute (NCI) Phase 2 RATIONALE: Stimulant drugs such as dextroamphetamine-amphetamine and methylphenidate may help improve memory, attention, and thinking problems caused by central nervous system (CNS) treatment for cancer, and may help decrease depression. PURPOSE: This randomized phase II trial is studying dextroamphetamine-amphetamine to see how well it works compared to methylphenidate in treating depression and problems with memory, attention, and thinking in children who have undergone CNS treatment for cancer. This trial will also study how often depression is seen and if these medications might help.
NCT00069927 Adderall XR Compared With Concerta in Treating Young Cancer Patients With Memory, Attention, and Depression Terminated University of South Florida Phase 2 RATIONALE: Stimulant drugs such as dextroamphetamine-amphetamine and methylphenidate may help improve memory, attention, and thinking problems caused by central nervous system (CNS) treatment for cancer, and may help decrease depression. PURPOSE: This randomized phase II trial is studying dextroamphetamine-amphetamine to see how well it works compared to methylphenidate in treating depression and problems with memory, attention, and thinking in children who have undergone CNS treatment for cancer. This trial will also study how often depression is seen and if these medications might help.
NCT00181571 A Double-Blind Comparison of Concerta and Placebo in Adults With Attention Deficit Hyperactivity Disorder Completed McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. Phase 4 This is a double-blind, placebo-controlled study using daily doses of up to 1.3 mg/kg/day of Concerta in the treatment of adults with the DSM-IV diagnosis of attention deficit hyperactivity disorder (ADHD) (childhood onset). We hypothesize ADHD symptomatology in adults with DSM-IV ADHD will be responsive to Concerta treatment and Concerta-associated response of ADHD symptomatology in adults will be sustained over time.
NCT00181571 A Double-Blind Comparison of Concerta and Placebo in Adults With Attention Deficit Hyperactivity Disorder Completed Massachusetts General Hospital Phase 4 This is a double-blind, placebo-controlled study using daily doses of up to 1.3 mg/kg/day of Concerta in the treatment of adults with the DSM-IV diagnosis of attention deficit hyperactivity disorder (ADHD) (childhood onset). We hypothesize ADHD symptomatology in adults with DSM-IV ADHD will be responsive to Concerta treatment and Concerta-associated response of ADHD symptomatology in adults will be sustained over time.
NCT00181714 Prevention of Cigarette Smoking in Attention Deficit Hyperactivity Disorder (ADHD) Youth With Concerta Completed Ortho-McNeil Janssen Scientific Affairs, LLC Phase 4 This study will consist of a six-week open-label treatment period with an extended duration methylphenidate (OROS MPH) followed by subsequent monthly visits for 24 months in a large sample of youths aged 12-17 who meet Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria for ADHD. The researchers hypothesize that OROS MPH treatment will be associated with low rates of cigarette smoking in ADHD youth.
NCT00181714 Prevention of Cigarette Smoking in Attention Deficit Hyperactivity Disorder (ADHD) Youth With Concerta Completed Massachusetts General Hospital Phase 4 This study will consist of a six-week open-label treatment period with an extended duration methylphenidate (OROS MPH) followed by subsequent monthly visits for 24 months in a large sample of youths aged 12-17 who meet Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria for ADHD. The researchers hypothesize that OROS MPH treatment will be associated with low rates of cigarette smoking in ADHD youth.
NCT00181740 Concerta Treatment in Adults With ADHD NOS Completed McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. Phase 4 This will be an open label pilot study of Concerta in the treatment of adults with the diagnosis of Attention Deficit Hyperactivity Disorder Not Otherwise Specified (ADHD NOS). We hypothesize ADHD symptomatology in adults with ADHD NOS will be responsive to Concerta treatment in the short term and Concerta-associated response of ADHD symptomatology in adults with ADHD NOS will be sustained over the medium term.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Concerta

Condition Name

Condition Name for Concerta
Intervention Trials
Attention Deficit Hyperactivity Disorder 27
Attention Deficit Disorder With Hyperactivity 11
ADHD 11
Healthy 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Concerta
Intervention Trials
Attention Deficit Disorder with Hyperactivity 57
Hyperkinesis 38
Disease 24
Fatigue 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Concerta

Trials by Country

Trials by Country for Concerta
Location Trials
United States 147
Canada 7
Sweden 3
France 2
Switzerland 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Concerta
Location Trials
Massachusetts 16
Ohio 12
Texas 10
New York 7
California 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Concerta

Clinical Trial Phase

Clinical Trial Phase for Concerta
Clinical Trial Phase Trials
Phase 4 41
Phase 3 15
Phase 2/Phase 3 1
[disabled in preview] 25
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Concerta
Clinical Trial Phase Trials
Completed 54
Recruiting 9
Unknown status 7
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Concerta

Sponsor Name

Sponsor Name for Concerta
Sponsor Trials
Massachusetts General Hospital 14
McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. 13
Ortho-McNeil Janssen Scientific Affairs, LLC 10
[disabled in preview] 20
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Concerta
Sponsor Trials
Other 72
Industry 41
NIH 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Express Scripts
AstraZeneca
Harvard Business School
Medtronic
Merck
Fish and Richardson
Julphar
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.